{"lc": 1, "type": "constructor", "id": ["langchain", "schema", "document", "Document"], "kwargs": {"metadata": {"source": "/home/guanzhideng145/research/ip_portal/patent_kg/patents/195-EP2398517(active).pdf"}, "page_content": "1 B 7 1 5\n\n8 9 3\n\n2 P E\n\nEuropaisches Patentamt European Patent Office Office europ\u00e9en des brevets\n\n(19)\n\n(11) EP 2 398 517 B1\n\n(12) EUROPEAN PATENT SPECIFICATION\n\n(45) Date of publication and mention of the grant of the patent: 20.04.2016 Bulletin 2016/16\n\n(51) Int Cl.:\n\nA61L 27/06 (2006.01) AG1L 27/22 (2006.01) AG1L 27/34 (2006.01) AG1L 27/54 (2006.01)\n\n(21) Application number: 10743393.0\n\n(86) International application number:\n\nPCT/CN2010/000216\n\n(22) Date of filing: 18.02.2010\n\n(87) International publication number: WO 2010/094212 (26.08.2010 Gazette 2010/34)\n\n(54) ANTIBACTERIAL SURFACE AND METHOD OF FABRICATION\n\nANTIBAKTERIELLE OBERFL\u00c4CHE UND VERFAHREN ZU IHRER HERSTELLUNG\n\nSURFACE ANTIBACT\u00c9RIENNE ET SON PROC\u00c9D\u00c9 D\u2019OBTENTION\n\n(84) Designated Contracting States:\n\nAT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR\n\nKAO, Yitsun, Richard\n\n* KAO, Yitsun, Richard Hong Kong (CN)\n\nHong Kong (CN) \u2022 CHU, Kimho, Paul Hong Kong (CN)\n\n(30) Priority: 19.02.2009 US 153840 P 20.02.2009 US 154278 P\n\n(43) Date of publication of application: 28.12.2011 Bulletin 2011/52\n\n(74) Representative: Epping - Hermann - Fischer\n\nPatentanwaltsgesellschaft mbH Postfach 20 07 34 80007 M\u00fcnchen (DE)\n\n(56) References cited:\n\n(73) Proprietors:\n\nVersitech Limited Hong Kong (CN)\n\nWO-A2-2008/085578 CN-A- 101 020 087\n\nCN-A- 1 933 859 CN-A- 101 128 224\n\n\u2022 City University of Hong Kong\n\nHong Kong (CN)\n\n(72) Inventors:\n\n\u2022 MANDL, S. ET AL.: \u2019Investigation on plasma immersion ion implantation treated medical implants.\u2019 BIOMOLECULAR ENGINEERING. vol. 19, 2002, pages 129 - 132, XP004378082\n\n\u2022 YEUNG, Waikwok, Kelvin\n\nHong Kong (CN) \u2022 CHEUNG, Manchee Hong Kong (CN) \u2022 LUK, Dipkei, Keith Hong Kong (CN) \u2022 YEUNG, Cheyan Hong Kong (CN)\n\n\u2022 N.D. RAWLINGS ET AL.: \"MEROPS: the peptide database\", NUCLEIC ACIDS RESEARCH, vol. 34, 1 January 2006 (2006-01-01), pages D270-D272, DOI: 10.1093/nar/gkj089\n\n\u2022 D.L. Nelson, M.M. Cox: \"Lehninger Principles of Biochemistry, 4th Ed.\", pages 99-100,\n\nNote: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).\n\nPrinted by Jouve, 75001 PARIS (FR)\n\n1\n\nEP 2 398 517 B1\n\n2\n\nDescription\n\nBACKGROUND OF THE INVENTION\n\nField of the Invention\n\n[0001] The present invention relates to controllable an- timicrobial and biocompatible titanium alloys for reducing post-operative implant-related bacterial infections. The present invention further relates to surface techniques and their mechanisms for modifying material surfaces so as to enhance the surface antimicrobial properties and achieve controllable release of antimicrobial peptides.\n\nDescription of the Related Art\n\n[0002] Biomaterials such as stainless steel and titani- um alloys are widely used in orthopaedic and dental sur- gery. Internal bone fracture fixations, spinal deformity corrections and total joint replacements are commonly seen in orthopaedic procedures in which metallic bioma- terials are usually used to maintain biomechanical integ- rity. However, adhesion and proliferation of microorgan- isms on these implants may induce post-operative mi- crobial infections. In addition, they may result in implant loosening or other serious complications. According to R.O. Darouiche in \"Treatment of Infections Associated with Surgical Implants\" (The New England Journal of Medicine 2004;350(14):1422-1429), two to five percent of the patients receiving orthopaedic procedures may be required to undergo revision surgery to remove or replace the infected implants. In addition to the increase in cost to the public healthcare system, the morbidity and mor- tality rates are undoubtedly increased. [0003] Surface modifications have been proposed to modify the surface properties of biomaterials so as to maintain their bulk mechanical properties after treatment. To reduce bacterial adhesion and proliferation, certain surface treatments such as antibiotic, silver and copper ions loaded surfaces have been studied. The fabrication of the surface treated implants have been carried out by the sol-gel technique, physical vapor deposition (PVD), chemical vapor deposition (CVD), immersion and ion im- plantation. Unfortunately, the release rate of those sur- face treatment deposits is difficult to manipulate by using the current technologies. In addition, as shown by S-H. Shin et al. in \"The effects of nano-silver on the prolifera- tion and cytokine expression by peripheral blood mono- nuclear cells\" Immunopharmacology 2007;7(13):1813-1818) and B.S. Atiyeh et al. in \"Effect of silver on burn wound infection control and healing: Review of the literature\" (Burns 2007;33(2): 139-148), silver and copper ions may poison the surrounding hu- man cells. [0004] Previous studies have also involved the loading of antibiotics such as vancomycin onto a titanium sub- strate surface via the sol-gel technique. One obstacle to prevalent use of this technique is the uncontrollable deg-\n\n5\n\n10\n\n15\n\n15\n\n20\n\n25\n\n30\n\n35\n\n40\n\n45\n\n50\n\n55\n\n55\n\nradation of antibiotics once exposed to body fluid. This effect is shown in \"Controlled release of vancomycin from thin sol-gel films on titanium alloy fracture plate material\" by S. Radin et al. (Biomaterials 2007;28(9):1721-1729) and \"In vivo tissue response to resorbable silica xerogels as controlled-release materials\" by S. Radin et al. (Bio- materials 2005;26(9):1043-1052). Accordingly, the re- lease rate of the antibiotic is difficult to control with the use of existing techniques. Clinically, deep wound infec- tion occurring after period of operation is not uncommonly seen. The conventional antibiotics coating is not able to tackle this complication due to the degradation over time of the antibiotics. The unprotected surface of the implant is then exposed to the invading bacteria. Moreover, the uncontrollable release of the antibiotics may occur in ex- cess and thus spoil the normal function of the peripheral cells. [0005] Thus, there continues to exist a need in the art for implantable biomaterials with surface antimicrobial properties.\n\nBRIEF SUMMARY OF THE INVENTION\n\n[0006] The present invention provides surgical im- plants as defined in claim 1. In a specific embodiment, the implantable titanium alloys are fabricated by using plasma immersion ion implantation and deposition (PI- II&D), pressurized hydrothermal treatment, and antimi- crobial peptide coating. Advantageously, these specially modified titanium alloys are able to suppress the adhe- sion and proliferation of microorganisms. [0007] Embodiments of the present invention involve performing surface techniques to modify the surface of a material in order to form one or several antimicrobial layers capable of resisting microbial adhesion and pro- liferation. [0008] In one embodiment, the surface modification techniques include PIII&D and/or a pressurized hydro- thermal treatment. In a further embodiment, a surface layer is fabricated by using a technique for the immobi- lization of controllable release antimicrobial peptides. Ac- cording to embodiments, an assembly of surface modi- fication techniques, or a combination of one or more of the technique(s) disclosed herein and one or more of the existing technique(s) such as antibiotics coating or silver doping can be used to fabricate the surface layer(s). [0009] According to one embodiment, the surface modification by using PIII&D can implant various sources including ions, electrons, free radicals, atoms and mole- cules onto the substrate surface as the basal surface to inhibit microbial adhesion and growth. This basal surface is able to resist the attachment of microorganisms and the formation of biofilm. However, advantageously, this surface allows the attachment and growth of mammalian cells. In a further embodiment, reactive functional [0010] groups such as -OH and -NH2 groups are incorporated onto the basal surface, forming an intermediate surface\n\n2\n\n3\n\nEP 2 398 517 B1\n\n4\n\nlayer to facilitate a linker molecule\u2019s coupling, for exam- ple, a linker such as 3-aminopropyltriethoxysilane (AP- TES). The fabrication of the reactive functional groups can be performed through a pressurized hydrothermal treatment or another PIII&D process. The antimicrobial peptides will then aggregate on the outermost layer of the titanium substrate to form an antimicrobial peptide coating. [0011] The subject titanium alloy modified by PIII&D treatment has the ability to resist bacterial adhesion and growth, and its modified surface is also compatible with mammalian cells. [0012] The release of antimicrobial peptides from the outermost layer is only triggered when bacteria start to attach to the titanium surface, and is thus self-controlla- ble. In contrast, for conventional antibiotic or antimicro- bial peptide coatings, the conventional release mecha- nism of the antibacterial peptide or antibiotics loaded sur- faces is subject to the exposure to the body fluids and therefore uncontrollable. [0013] The present invention can be applied to ortho- paedic implants, but embodiments are not limited thereto. For example, the present invention can be applied to all implantable biomaterials such as cardiovascular im- plants and dental implants.\n\nBRIEF DESCRIPTION OF THE DRAWINGS\n\n[0014] The patent or application file contains at least one drawing executed in color. Copies of this patent or patent application publication with color drawing(s) will be provided by the Office upon request and payment of the necessary fee. [0015] The detailed description of the present inven- tion will be better understood in conjunction with the ac- companying drawings, wherein like reference characters represent like elements, as follows:\n\nFigure 1 is a table providing the PIII&D surface treat- ment conditions of titanium alloy samples. Figure 2A is an XPS elemental depth profile of an untreated titanium alloy control. Figure 2B is an XPS elemental depth profile of a 50 Hz oxygen PIII&D treated titanium alloy sample fab- ricated in accordance with an embodiment of the present invention. Figure 2C is an XPS elemental depth profile of a 100 Hz oxygen PIII&D treated titanium alloy sample fab- ricated in accordance with an embodiment of the present invention. Figure 3A is an image of the AFM surface topography on the untreated titanium alloy control. Figure 3B is an image of the AFM surface topography on a 50 Hz oxygen PIII&D treated titanium alloy sam- ple fabricated in accordance with an embodiment of the present invention. Figure 3C is an image of the AFM surface topography on a 100 Hz oxygen PIII&D treated titanium alloy\n\n5\n\n10\n\n15\n\n20\n\n25\n\n30\n\n35\n\n40\n\n45\n\n50\n\n55\n\nsample fabricated in accordance with an embodi- ment of the present invention. Figure 4 is a graph showing number of adhered bac- teria Staphylococcus aureus on the untreated titani- um alloy and 50Hz and 100Hz oxygen PIII&D treated titanium alloy samples after one hour of bacteria cul- turing. Figure 5A is a fluorescent micrograph of an untreated control titanium alloy sample. The green marks rep- resent live Staphylococcus aureus. Figure 5B is the fluorescent micrograph of a 50 Hz oxygen PIII&D treated titanium alloy sample fabri- cated in accordance with an embodiment of the present invention. The green and red marks repre- sent live and dead Staphylococcus aureus respec- tively. Figure 5C is the fluorescent micrograph of a 100 Hz oxygen PIII&D treated titanium alloy sample fabri- cated in accordance with an embodiment of the present invention. The green and red marks repre- sent live and dead Staphylococcus aureus respec- tively. Figure 6A is a fluorescent micrograph of an untreated control titanium alloy sample. The green marks rep- resent live mammalian cells of EGFP-expressing mouse osteoblasts. Figure 6B is the fluorescent micrograph of a 50 Hz oxygen PIII&D treated titanium alloy sample fabri- cated in accordance with an embodiment of the present invention. The green marks represent live mammalian cells of EGFP-expressing mouse oste- oblasts. Figure 6C is the fluorescent micrograph of a 100 Hz oxygen PIII&D treated titanium alloy sample fabri- cated in accordance with an embodiment of the present invention. The green marks represent live mammalian cells of EGFP-expressing mouse oste- oblasts. Figure 7 is an illustration of the controllable release mechanism utilized in an embodiment of the present invention. The bacterial protease cleaves the pep- tide bonding at the C-terminal side of glutamic acid and allows the release of antibacterial peptide. Figure 8A is a titanium alloy implant incorporated with an antibacterial peptide through linker mole- cules such as APTES. Figure 8B is the chemical structure of a linker mole- cule APTES. Figure 8C is the chemical structure of an antibacterial peptide for immobilization on the titanium alloy im- plant. This is an example peptide that is incorporated onto the outermost layer of an implantable metallic surface according to an embodiment of the present invention. Figure 9 is an illustration of the fabrication process of antibacterial layers on the substrate surface with the application of grid. The grid with longitudinal lines is placed to cover the substrate surface (on the left).\n\n3\n\n5\n\nEP 2 398 517 B1\n\n6\n\nAfter the application of PIII&D, lines of the antibac- terial layer are formed (on the right). By shifting the grid, alternate lines of antibacterial basal layer and peptide layer can be obtained (the order of applying PIII&D and peptide can be reversed).\n\nDETAILED DISCLOSURE OF THE INVENTION\n\n[0016] Embodiments of the present invention provide one or more antimicrobial layers capable of resisting mi- crobial adhesion and proliferation on a material surface. According to implementations of the present invention, the surface techniques of plasma immersion ion implan- tation and deposition (PIII&D) and pressurized hydro- thermal treatment, and the methods of immobilizing an- timicrobial peptides onto the material surfaces are used to enhance the antimicrobial properties of a material sur- face. [0017] To reduce and potentially eliminate the techni- cal complications of existing antimicrobial techniques, the fabricating of the antimicrobial surface with the use of PIII&D, pressurized hydrothermal treatment, and an- timicrobial peptide coating as described in embodiments herein, provides an alternative to suppress the adhesion and proliferation of microorganisms. [0018] Embodiments of the present invention provide a controllable antimicrobial and biocompatible Ti alloy that can resist bacterial adhesion and proliferation with- out compromising its biocompatibility and original me- chanical properties. The controllable antimicrobial and biocompatible Ti alloy of embodiments of the present in- vention can resist microbial adhesion and proliferation by using surface techniques including PIII&D, intermedi- ate linker formation, and the immobilization of controlla- ble release antimicrobial peptides on the outmost sur- face. The medical applications of this special titanium alloy can include but are not limit to orthopaedic surger- ies, cardiovascular, and dental operations. [0019] For PIII&D, various sources including ions, electrons, free radicals, atoms and molecules can be im- planted onto the substrate surface as the basal surface to protect against microbial adhesion and growth. This basal surface is able to resist the attachment of microor- ganisms and the formation of biofilm. [0020] For the pressurized hydrothermal treatment, functional groups of interest can be incorporated onto the substrate surface as another basal surface to resist microbial adhesion and proliferation. [0021] The second layer next to or on top of the afore- mentioned basal surface can be fabricated and covered by antimicrobial peptides. The antimicrobial peptide coat- ing formed in accordance with the present invention per- forms such that the release of antimicrobial peptide is triggered when the microorganisms start to attach to the surface. In contrast, the conventional release mecha- nism of antibiotics loaded surfaces are subject to the ex- posure to the body fluids, and are therefore uncontrolla- ble. According to an embodiment, the antimicrobial pep-\n\n5\n\n10\n\n15\n\n20\n\n25\n\n30\n\n35\n\n40\n\n45\n\n50\n\ntide is capable of performing differently than the conven- tional antibiotics based on a controllable manner in which the antimicrobial peptides will be cleaved off from the surface by the proteins or enzymes secreted by those incoming microorganisms. The released peptides can then terminate the incoming microorganisms. This de- fense mechanism is comparatively long lasting and more stable than the conventional approaches. This combined mechanism can be applied to various medical implants made of metals, alloys, ceramics, polymers, composites and hybrid materials, and even the medical implants with irregular shapes. [0022] In accordance with embodiments, implantable Ti alloys are provided with controllable antimicrobial and biocompatible properties for reducing post-operative im- plant-related bacterial infections. Certain embodiments having these controllable properties can resist infections both short term and long term (6 months or more) post- operatively. [0023] It should be noted that when the substrate ma- terial and/or location of application are altered, an option- al optimization of the sources and/or parameters of the surface techniques can be performed. For instance, an optimization of the plasma source, application frequency, voltage and duration of implantation can be involved when applying the PIII&D technique. Furthermore, the antimicrobial ability of implantable titanium alloy may in- volve an optimization of the sources and/or parameters of PIII&D, e.g. plasma source, application frequency, voltage, and duration of implantation. The parameters of the PIII&D include using a plasma source of at least one of water, oxygen, ammonia, fluorine, nitrogen, gold, sil- ver, copper, silicon-carbine, iridium oxide, carbon, and diamond like carbon; an implantation voltage in a range of 1kV - 100kV; a frequency in a range of 1 Hz - 1,000Hz; and a period of time in a range of 1 min - 100 hours. [0024] In another embodiment, an optimization of the composition, sequence and amount of the antimicrobial peptide and the species of linker molecules connecting antimicrobial peptide and the substrate can be involved when immobilizing the peptide on the material surface. For example, the composition, sequence and amount of the antimicrobial peptide and the species of linker mole- cules connecting antimicrobial peptide and the titanium substrate may also alter its antimicrobial ability when im- mobilizing the peptides on the material surface. Thermal treatment and/or radiation treatment to the biomaterials such as the titanium alloy can further be involved during the fabrication process so as to enhance the antimicrobial properties of these surface layers and alloys. [0025] In order to better understand the present inven- tion, a titanium alloy treated by PIII&D oxygen will be used as one of examples to highlight its antibacterial properties and biocompatibility.\n\n55\n\nAntimicrobial Basal Layer Fabricated by PIII&D\n\n[0026] An antimicrobial basal layer on an implantable\n\n4\n\n7\n\nEP 2 398 517 B1\n\n8\n\ntitanium alloy can be fabricated by incorporating ions, electrons, free radicals, atoms and molecules onto its surface using, for example, oxygen, water, ammonia, flu- orine, nitrogen, gold, silicon-carbide, iridium oxide, car- bon or diamond-like carbon. The techniques used to modify the surface of the implant can involve PIII&D and/or other treatments such as a pressurized hydrother- mal treatment. In general, the newly-formed layer(s) pos- sesses antimicrobial properties and biocompatibility, thereby protecting the metallic surface of the implant from microbial attack and accommodating for the growth of mammalian cells. [0027] In an embodiment of the titanium alloy treated by oxygen PIII&D, the material surface of the titanium alloy implant is surrounded by high density oxygen plas- ma and biased to a high negative potential relative to the chamber in which the oxygen plasma source is generated by a high voltage AC/DC supply. The oxygen plasma ions are accelerated across the sheath formed around the substrate (titanium alloy implant) by an electromag- netic field and implanted onto the surface of the substrate (titanium alloy implant). Both the dose of the implanted ions and the depth of the implanted layer can be opti- mized by adjusting the plasma density, pulse width, ap- plied voltage and repetition frequency in order to enhance the antimicrobial property. [0028] According to an example implementation pro- viding surface chemical characteristics of the oxygen PI- II&D treated titanium alloys, the elemental depth profile is investigated by X-ray photoelectron spectroscopy (XPS) so as to reveal the surface composition of the sam- ples. For these samples, polished and cleaned medical grade titanium Ti-6A1-4V discs with 5 mm diameter and 1 mm thickness were implanted with oxygen plasma us- ing a PIII&D technique in accordance with an embodi- ment of the present invention. Fig. 1 shows a Table in- dicating the treatment conditions of the embodying oxy- gen PIII&D samples described in this disclosure, while Fig. 2A shows the results of an untreated titanium sam- ple, Fig. 2B shows the chemical profiles of the 50 Hz oxygen treated samples, and Fig. 2C shows the chemical profile of the 100 Hz oxygen treated samples. It can be observed from the figures that the oxygen content has been enriched at the Ti alloy surface. In addition, the thickness of the oxygen rich layer can be increased with the implantation frequency. [0029] In the same example implementation, the treat- ed titanium surface topography and roughness is evalu- ated by atomic force microscopy (AFM). The results of the untreated and treated samples are shown in Figs. 3A-3C. The surface roughness can be indicated by the root mean square (RMS) value of the AFM surface to- pography plot of the samples. The RMS of the control is 40 \u00c5, the RMS of the 50 Hz oxygen treated sample is 22 \u00c5, and the RMS of the 100 Hz oxygen treated sample is 24 \u00c5. As indicated by Figs. 3A-3C, it can be seen that the treated surfaces are smoothened as compared to the non-treated surface. In particular, the roughness of the\n\n5\n\n10\n\n15\n\n20\n\n20\n\n25\n\n30\n\n30\n\n35\n\n40\n\n45\n\n50\n\n50\n\ntitanium surface was reduced after treatment. In addition, a specific surface pattern (ripple-like pattern) appeared on the titanium surface after it was modified by the oxygen PIII&D. This ripple-like pattern can help reduce bacterial adhesion and attachment. [0030] The antibacterial/antimicrobial properties of the specially treated titanium alloys in accordance with the present invention have been characterized by standard colony forming unit (CFU) counting with Staphylococcus aureus, which is commonly seen in orthopaedic implant- related infection. The Staphylococcus aureus adhered on the metallic surfaces was detached by sonication. The CFU of the detached bacteria suspension is determined by surface plating on Brain Heart Infusion (BHI) agar after being incubated at 37\u00b0C for 24 hrs. As demonstrated in the graph of Fig. 4, the reduction of bacterial adhesion on treated titanium surfaces is significant after the PIII&D surface treatments in accordance with the present inven- tion. [0031] Antibacterial/antimicrobial properties of the treated titanium surfaces can also be visualized by ap- plying fluorescent microscopy. Figs. 5A-5C show the morphology of adhered bacteria on the untreated and treated titanium alloys. It can be easily observed by com- paring Fig. 5A to Figs. 5B and 5C that the titanium alloy treated with oxygen PIII&D successfully inhibits the ad- hesion of Staphylococcus aureus. [0032] Furthermore, with respect to the biocompatibil- ity of treated titanium alloys in accordance with embod- iments of the present invention, mammalian cell culturing using EGFP-expressing mouse osteoblasts have been conducted and are visualized by applying fluorescent mi- croscopy. Figs. 6A-6C show the morphology of adhered mammalian cells on the untreated and treated titanium alloys. The results revealed that the titanium surfaces treated with 50 Hz and 100 Hz oxygen plasma treatment (Figs. 6B and 6C, respectively) are well tolerated by mammalian cells as compared with the untreated titani- um (Fig. 6 A) after 3 days of culturing. In another embodiment, a pressurized hydro- [0033] thermal treatment can be applied to establish reactive functional groups exhibiting antimicrobial functions. For example, implantable titanium alloy with other reactive functional groups such as -OXHY (where x and y are nat- ural numbers) exhibiting antimicrobial functions can be achieved by the pressurized hydrothermal treatment. In yet another embodiment, PIII&D can be used to form a reactive functional amide group (for example -NH2) on the titanium alloy surface. For example, nitrogen, oxygen, and ammonia PIII&D can be performed under various conditions (including concentration of implanted ele- ments, implantation voltage and frequency, treatment time, and temperature) to form the reactive functional amide groups on the titanium alloy surface. [0034] However, the reactive function group layer is not functional groups. For example, these reactive functional groups can be regarded as an intermediate surface to facilitate\n\n55\n\n55\n\n5\n\n9\n\nEP 2 398 517 B1\n\n10\n\nthe formation of linker molecules such as APTES. Then, the linker molecules can be used to aggregate external antimicrobial molecules such as chitosan and antimicro- bial peptides on the surface of implantable titanium al- loys. This mechanism is discussed in the example below.\n\nControllable Release Antimicrobial Peptide\n\n[0035] A titanium alloy having a layer of antimicrobial peptide can be fabricated on the substrate surfaces alone, next to or on top of the aforementioned basal layer, or in a combination with other existing antimicrobial sur- face techniques such as coating and plasma spraying. For example, an implantable titanium alloy with a coating of controllable release antimicrobial peptide on its outer- most surface can be fabricated by surface treatments such as conventional coating and plasma spraying. [0036] The antimicrobial peptide on the plasma treated titanium alloy according to an embodiment is fabricated to provide a controllable manner in which the antimicro- bial peptides will be cleaved off from the substrate surface by the proteins or enzymes secreted by those incoming microorganisms. [0037] The subject implantable titanium alloy with an- timicrobial peptide coating possesses a manner of con- trollable release. The antimicrobial peptides will be cleaved off from the titanium surface when the proteins or enzymes secreted by the particular incoming bacteria as the bacterial approach the implant. The released pep- tides can then terminate the incoming microorganisms. In an embodiment of antibacterial peptide immobilized titanium alloy orthopaedic implants, the V8 protease se- creted by the Staphylococcus aureus cleaves the peptide bonding of the antibacterial peptide at the C-terminal side of glutamic acid. This mechanism is demonstrated in Fig. 7. The controllable release mechanism of antibacterial peptides can be applied to orthopaedic, dental and car- diovascular implants so as to work against bacteria such as Staphylococcus aureus, Pseudomonas aeruginosa, Staphylococcus epidermidis, Salmonella Dublin, Es- cherichia coli, Porphyromonas gingivalis, and Strepto- coccus mutans, etc. [0038] In order to immobilize the antimicrobial peptides onto the titanium surfaces, reactive functional groups and linkers are preferably incorporated to the metallic sub- strate first so as to facilitate the subsequent peptide at- tachment. As mentioned above, reactive functional groups fabricated on the titanium substrate surfaces by pressurized hydrothermal treatment (or PIII&D) may also contain antimicrobial functions. Alternatively, these func- tional groups can also be regarded as an intermediate surface to facilitate the formation of linker molecules such as APTES such that the antimicrobial substances such as chitosan and antibacterial peptides can aggregate on the surface of implantable titanium alloys. [0039] In an embodiment, the implantable titanium al- loy with a layer of hydroxide functional groups (-OH) can be established by submerging the metal (titanium alloy)\n\n5\n\n10\n\n10\n\n15\n\n20\n\n25\n\n30\n\n35\n\n35\n\ninto a hydrogen peroxide solution followed by a series of heating processes under pressurized conditions. A sec- ond reagent such as concentrated sodium hydroxide so- lution may be used to enhance the yield of -OH functional groups. For those metallic surfaces with -OH functional groups after pressurized hydrogen peroxide treatment, the antibacterial/antimicrobial peptides are able to cov- alently attach to the -OH groups on the titanium alloy substrate surface by applying coupling agents (linkers). For instance, 3-aminopropyltriethoxysilane (APTES) can be used as one of the coupling agents. One end of the APTES linker can be attached to the -OH group on the titanium alloy substrate surface and the other end with a primary amine group can be linked up with other linkers and/or antibacterial/antimicrobial peptides. The amine group at the APTES linker can be easily converted into other functional groups such as COOH by various chem- ical reactions such as oxidation and carbonation. [0040] Figs. 8A-8C illustrate the attachment of an an- tibacterial/antimicrobial peptide to the titanium alloy in which its surface is firstly treated with pressurized hydro- thermal treatment and followed by the attachment of AP- TES linkers and glutaric anhydride. The antibacterial/an- timicrobial peptide can be subsequently incorporated to the free end of the APTES linker or glutaric anhydride. Fig. 8A shows the chemical structure of the embodiment of an antibacterial/antimicrobial peptide immobilized on a titanium alloy implant surface. Figs. 8B and 8C show the chemical structure of APTES molecule and antibac- terial peptide, respectively. [0041] During the fabrication process, particular grids (or masks) can be applied to cover partial areas of the substrate so as to establish various patterns over the metallic substrate surface, thereby forming specific pat- terns of antibacterial/antimicrobial peptides and surfaces on the titanium alloy as shown in Fig. 9. In an embodi- ment, if the grid with longitudinal lines is applied through- out the fabrication process, alternate lines of antibacterial basal layer and peptide layer on the substrate surface can be resulted.\n\n40\n\nClaims\n\n45\n\n1. A surgical implant comprising:\n\n50\n\n55\n\na titanium alloy modified by a plasma treatment and having a controllable release antimicrobial peptide coating disposed on the surface of the modified titanium alloy, wherein the controllable release antimicrobial peptide coating has a controllable release mechanism for the antimicrobial peptide that is triggered by an incoming bacterial attack, wherein the controllable release antimicrobial peptide coating includes stable antimicrobial peptides having a cleavable mechanism that is triggered by protease released by incoming bac-\n\n6\n\n11\n\nEP 2 398 517 B1\n\n12\n\nteria, and wherein the surface of the modified titanium alloy is compatible with mammalian cells.\n\n2. The surgical implant according to claim 1, wherein the modified titanium alloy is able to resist bacterial attachment and growth on its surface.\n\n5\n\n11. The surgical implant according to claim 10, wherein release of antimicrobial peptides from the controlla- ble release antimicrobial peptide coating is triggered by breakdown of the linker molecules, wherein the breakdown of linker molecules is triggered by incom- ing bacteria.\n\n3. The surgical implant according to claim 1, wherein original mechanical properties of the titanium alloy are not altered by the plasma treatment and antimi- crobial peptide coating.\n\n4. The surgical implant according to claim 1, wherein the modified titanium alloy is configured for implan- tation in orthopaedic, cardiovascular, or dental op- erations.\n\n5. The surgical implant according to claim 1, wherein the plasma treatment process involves plasma im- mersion ion implantation and deposition (PIII&D), and the parameters of the PIII&D include a plasma source of at least one of water, oxygen, ammonia, fluorine, nitrogen, gold, silver, copper, silicon-car- bine, iridium oxide, carbon, and diamond like carbon, an implantation voltage in a range of 1kV - 100kV, a frequency in a range of 1 Hz - 1,000Hz, and duration of time in a range of 1 min - 100 hours.\n\n6. The surgical implant according to claim 1, wherein the modified titanium alloy has a surface topography of a ripple-like pattern.\n\n10\n\n15\n\n20\n\n25\n\n30\n\n12. The surgical implant according to claim 10, further comprising an intermediate layer formed by reactive functional groups, preferably comprising an -OH group, wherein the -OH group is fabricated by pres- surized hydrogen peroxide treatment and a series of heating processes or an amide group (-NH2), wherein the amide group is fabricated by nitrogen, oxygen and ammonia plasma immersion ion implan- tation, on the plasma treated titanium alloy surface, wherein the intermediate layer facilitates linker mol- ecule coupling on the plasma treated titanium alloy surface and facilitates antimicrobial peptide aggre- gation when forming the controllable release antimi- crobial peptide coating.\n\n13. The surgical implant according to claim 12, wherein the reactive functional group includes an -OH group, wherein the linker molecule includes APTES, where- in the APTES attaches at one end to the -OH group on the plasma treated titanium surface, wherein an- other end of the APTES having a primary amine group links up with additional linkers and/or antimi- crobial peptides and the primary amine group at the another end of the APTES is converted into a second functional group by a series of chemical reactions.\n\n7. The surgical implant according to claim 1, wherein the controllable release antimicrobial peptide coat- ing is effective against at least one of Staphylococ- cus aureus, Pseudomonas aeruginosa, Staphyloco- ccus epidermidis, Salmonella Dublin, Escherichia coli, Porphyromonas gingivalis, and Streptococcus mutans.\n\n8. The surgical implant according to claim 1, wherein the antimicrobial peptides of the controllable release antimicrobial peptide coating include anionic pep- tides, cationic peptides, anionic and cationic pep- tides that contain cysteine and form disulfide bonds, or catioinic peptides enriched for specific amino acid attachment.\n\n9. The surgical implant according to claim 1, wherein the modified titanium alloy is capable of withstanding short-term and long-term deep tissue infection.\n\n10. The surgical implant according to claim 1, further comprising linker molecules between the plasma treated titanium alloy surface and the antimicrobial peptide coating, preferably comprising 3-aminopro- pyltriethoxysilane (APTES).\n\nPatentanspr\u00fcche\n\n35\n\n1. Chirurgisches Implantat, umfassend:\n\n40\n\n40\n\n45\n\n50\n\n55\n\neine Titanlegierung, die durch eine Plasmabe- handlung modifiziert worden ist, und die eine an- timikrobielle Peptidbeschichtung zur kontrollier- baren Freisetzung aufweist, die auf der Oberfl\u00e4- che der modifizierten Titanlegierung angeord- net ist, wobei die antimikrobielle Peptidbeschichtung zur kontrollierbaren Freisetzung einen kontrol- lierbaren Freisetzungsmechanismus f\u00fcr das an- timikrobielle Peptid aufweist, der durch einen ankommenden Bakterienbefall ausgel\u00f6st wird, wobei die antimikrobielle Peptidbeschichtung zur kontrollierbaren Freisetzung stabile antimi- krobielle Peptide beinhaltet, mit einem spaltba- ren Mechanismus, der durch Protease ausge- l\u00f6st wird, die durch ankommende Bakterien frei- gesetzt wird, und wobei die Oberfl\u00e4che der modifizierten Ti- tanlegierung mit S\u00e4ugetierzellen kompatibel ist.\n\n7\n\n13\n\nEP 2 398 517 B1\n\n14\n\n2. Chirurgisches Implantat nach Anspruch 1, wobei die modifizierte Titanlegierung einer bakteriellen Anhaf- tung und dem Wachstum auf ihrer Oberfl\u00e4che wider- stehen kann.\n\n3. Chirurgisches Implantat nach Anspruch 1, wobei die urspr\u00fcnglichen mechanischen Eigenschaften der Ti- tanlegierung durch die Plasmabehandlung und die antimikrobielle Peptidbeschichtung nicht ver\u00e4ndert werden.\n\n5\n\n10\n\nellen Peptidbeschichtung umfasst, die vorzugswei- se 3-Aminopropyltriethoxysilan (APTES) umfassen.\n\n11. Chirurgisches Implantat nach Anspruch 10, wobei die Freisetzung von antimikrobiellen Peptiden aus der antimikrobiellen Peptidbeschichtung zur kontrol- lierbaren Freisetzung durch Abbau der Linkermole- k\u00fcle ausgel\u00f6st wird, wobei der Abbau der Linkermo- lek\u00fcle durch ankommende Bakterien ausgel\u00f6st wird.\n\n4. Chirurgisches Implantat nach Anspruch 1, wobei die modifizierte Titanlegierung f\u00fcr die Implantation bei orthop\u00e4dischen, kardiovaskul\u00e4ren oder Zahnopera- tionen konfiguriert ist.\n\n5. Chirurgisches Implantat nach Anspruch 1, wobei das Plasmabehandlungsverfahren Plasma-Immersi- ons-Ionenimplantation und Abscheidung (PIII&D) beinhaltet, und die Parameter von PIII&D eine Plas- maquelle von mindestens einem von Wasser, Sau- erstoff, Ammoniak, Fluor, Stickstoff, Gold, Silber, Kupfer, Siliciumcarbid, Iridiumoxid, Kohlenstoff und diamantartigem Kohlenstoff, eine Implantations- spannung in einem Bereich von 1kV - 100kV, eine Frequenz in einem Bereich von 1 Hz - 1000 Hz und eine Zeitdauer in einem Bereich von 1 min - 100 Stunden umfassen.\n\n15\n\n12. Chirurgisches Implantat nach Anspruch 10, zudem umfassend eine durch reaktive funktionelle Gruppen gebildete Zwischenschicht, die vorzugsweise eine -OH-Gruppe, wobei die -OH-Gruppe durch Behand- lung mit unter Druck stehendem Wasserstoffperoxid und eine Reihe von Erhitzungsverfahren erzeugt wird, oder eine Amidgruppe (-NH2) enth\u00e4lt, wobei die Amidgruppe durch Stickstoff-, Sauerstoff- und Ammoniak-Plasma-Immersions-Ionenimplantation auf der plasmabehandelten Titanlegierungsoberfl\u00e4- che erzeugt wird, wobei die Zwischenschicht die Lin- kermolek\u00fclkopplung auf der plasmabehandelten Ti- tanlegierungsoberfl\u00e4che erleichtert und die antimi- krobielle Peptidaggregation bei der Bildung der an- timikrobiellen Peptidbeschichtung zur kontrollierba- ren Freisetzung erleichtert.\n\n6. Chirurgisches Implantat nach Anspruch 1, wobei die modifizierte Titanlegierung eine Oberfl\u00e4chentopo- graphie eines wellenartigen Musters aufweist.\n\n7. Chirurgisches Implantat nach Anspruch 1, wobei die antimikrobielle Peptidbeschichtung zur kontrollier- baren Freisetzung gegen mindestens einen Mikro- organismus von Staphylococcus aureus, Pseudo- monas aeruginosa, Staphylococcus epidermidis, Salmonella Dublin, Escherichia coli, Porphyromo- nas gingivalis und Streptococcus mutans wirksam ist.\n\n30\n\n13. Chirurgisches Implantat nach Anspruch 12, wobei die reaktive funktionelle Gruppe eine -OH-Gruppe enth\u00e4lt, wobei das Linkermolek\u00fcl APTES umfasst, wobei APTES an einem Ende an die -OH-Gruppe auf der plasmabehandelten Titanoberfl\u00e4che gebun- den ist, wobei das andere Ende von APTES, das eine prim\u00e4re Amingruppe hat, mit zus\u00e4tzlichen Lin- kern und/oder antimikrobiellen Peptiden verbunden ist, und die prim\u00e4re Amingruppe am anderen Ende von APTES durch eine Reihe von chemischen Re- aktionen in eine zweite funktionelle Gruppe umge- wandelt wird.\n\nRevendications\n\n8. Chirurgisches Implantat nach Anspruch 1, wobei die antimikrobiellen Peptide der antimikrobiellen Peptid- beschichtung zur kontrollierbaren Freisetzung anio- nische Peptide, kationische Peptide, anionische und kationische Peptide, die Cystein enthalten und Di- sulfidbindungen bilden, oder kationische Peptide, die in Bezug auf spezifische Aminos\u00e4urebindung an- gereichert sind, umfassen.\n\n9. Chirurgisches Implantat nach Anspruch 1, wobei die modifizierte Titanlegierung kurzfristiger und langfris- tiger Tiefengewebe-Infektion standhalten kann.\n\n10. Chirurgisches Implantat nach Anspruch 1, das zu- dem Linkermolek\u00fcle zwischen der plasmabehandel- ten Titanlegierungs-Oberfl\u00e4che und der antimikrobi-\n\n55\n\nImplant chirurgical comprenant :\n\nun alliage de titane modifi\u00e9 par un traitement par plasma et ayant un rev\u00eatement de peptides an- timicrobiens \u00e0 lib\u00e9ration contr\u00f4lable dispos\u00e9 sur la surface de l\u2019alliage de titane modifi\u00e9, le rev\u00eatement de peptides antimicrobiens \u00e0 li- b\u00e9ration contr\u00f4lable ayant un m\u00e9canisme de li- b\u00e9ration contr\u00f4lable pour le peptide antimicro- bien qui est d\u00e9clench\u00e9 par une attaque bact\u00e9- rienne entrante, le rev\u00eatement de peptides an- timicrobiens \u00e0 lib\u00e9ration contr\u00f4lable comportant des peptides antimicrobiens stables ayant un m\u00e9canisme de clivage qui est d\u00e9clench\u00e9 par une prot\u00e9ase lib\u00e9r\u00e9e par des bact\u00e9ries entrantes,\n\n8\n\n15\n\nEP 2 398 517 B1\n\n16\n\n2.\n\n3.\n\net la surface de l\u2019alliage de titane modifi\u00e9 \u00e9tant compatible avec les cellules de mammif\u00e8res.\n\nImplant chirurgical selon la revendication 1, dans le- quel l\u2019alliage de titane modifi\u00e9 est capable de r\u00e9sister \u00e0 la fixation et la croissance de bact\u00e9ries sur sa sur- face.\n\nImplant chirurgical selon la revendication 1, dans le- quel les propri\u00e9t\u00e9s m\u00e9caniques initiales de l\u2019alliage de titane ne sont pas modifi\u00e9es par le traitement par plasma et le rev\u00eatement de peptides antimicrobiens.\n\n5\n\n10\n\nnant en outre des mol\u00e9cules de liaison entre la sur- face de l\u2019alliage de titane trait\u00e9 par plasma et le re- v\u00eatement de peptides antimicrobiens, comprenant de pr\u00e9f\u00e9rence du 3-aminopropyltri\u00e9thoxysilane (AP- TES).\n\n11. Implant chirurgical selon la revendication 10, dans lequel la lib\u00e9ration de peptides antimicrobiens du re- v\u00eatement de peptides antimicrobiens \u00e0 lib\u00e9ration contr\u00f4lable est d\u00e9clench\u00e9e par la rupture des mol\u00e9- cules de liaison, la rupture des mol\u00e9cules de liaison \u00e9tant d\u00e9clench\u00e9e par des bact\u00e9ries entrantes.\n\n4.\n\nImplant chirurgical selon la revendication 1, dans le- quel l\u2019alliage de titane modifi\u00e9 est configur\u00e9 pour une implantation dans des op\u00e9rations orthop\u00e9diques, cardiovasculaires, ou dentaires.\n\nImplant chirurgical selon la revendication 1, dans le- quel le proc\u00e9d\u00e9 de traitement par plasma implique l\u2019implantation et le d\u00e9p\u00f4t d\u2019ions par immersion dans un plasma (PIII&D), et les param\u00e8tres du PIII&D comportent une source de plasma d\u2019au moins un \u00e9l\u00e9ment parmi l\u2019eau, l\u2019oxyg\u00e8ne, l\u2019ammoniac, le fluor, l\u2019azote, l\u2019or, l\u2019argent, le cuivre, le carbure de silicium, l\u2019oxyde d\u2019iridium, le carbone et le carbone diamant, une tension d\u2019implantation dans une gamme de 1 kV - 100 kV, une fr\u00e9quence dans une gamme de 1 Hz - 1000 Hz, et une dur\u00e9e dans une gamme de 1 min - 100 heures.\n\n15\n\n12. Implant chirurgical selon la revendication 10, com- prenant en outre une couche interm\u00e9diaire form\u00e9e par des groupes fonctionnels r\u00e9actifs, comprenant de pr\u00e9f\u00e9rence un groupe -OH, le groupe -OH \u00e9tant fabriqu\u00e9 par traitement au peroxyde d\u2019hydrog\u00e8ne sous pression et une s\u00e9rie de proc\u00e9d\u00e9s de chauffa- ge, ou un groupe amide (-NH2), le groupe amide \u00e9tant fabriqu\u00e9 par implantation d\u2019ions par immersion dans un plasma d\u2019azote, d\u2019oxyg\u00e8ne et d\u2019ammoniac, sur la surface de l\u2019alliage de titane trait\u00e9 par plasma, la couche interm\u00e9diaire facilitant le couplage de mo- l\u00e9cules de liaison sur la surface de l\u2019alliage de titane trait\u00e9 par plasma et facilitant l\u2019agr\u00e9gation de peptides antimicrobiens lors de la formation du rev\u00eatement de peptides antimicrobiens \u00e0 lib\u00e9ration contr\u00f4lable.\n\nImplant chirurgical selon la revendication 1, dans le- quel l\u2019alliage de titane modifi\u00e9 a une topographie de surface d\u2019un motif en forme d\u2019ondulations.\n\n6.\n\nImplant chirurgical selon la revendication 1, dans le- quel le rev\u00eatement de peptides antimicrobiens \u00e0 li- b\u00e9ration contr\u00f4lable est efficace contre au moins une bact\u00e9rie parmi Staphylococcus aureus, Pseudomo- nas aeruginosa, Staphylococcus epidermidis, Sal- monella Dublin, Escherichia coli, Porphyromonas gingivalis, et Streptococcus mutans.\n\n35\n\n40\n\n13. Implant chirurgical selon la revendication 12, dans lequel le groupe fonctionnel r\u00e9actif comporte un groupe -OH, dans lequel la mol\u00e9cule de liaison com- porte de l\u2019APTES, dans lequel l\u2019APTES se fixe \u00e0 une extr\u00e9mit\u00e9 au groupe -OH sur la surface de titane trai- t\u00e9 par plasma, dans lequel une autre extr\u00e9mit\u00e9 de l\u2019APTES ayant un groupe amine primaire se fixe \u00e0 des lieurs et/ou des peptides antimicrobiens suppl\u00e9- mentaires et le groupe amine primaire \u00e0 l\u2019autre ex- tr\u00e9mit\u00e9 de l\u2019APTES est transform\u00e9 en un deuxi\u00e8me groupe fonctionnel par une s\u00e9rie de r\u00e9actions chimi- ques.\n\nImplant chirurgical selon la revendication 1, dans le- quel les peptides antimicrobiens du rev\u00eatement de peptides antimicrobiens \u00e0 lib\u00e9ration contr\u00f4lable comprennent des peptides anioniques, des peptides cationiques, des peptides anioniques et cationiques qui contiennent de la cyst\u00e9ine et forment des liaisons disulfure, ou des petites cationiques enrichis pour la fixation d\u2019un acide amin\u00e9 sp\u00e9cifique.\n\n9.\n\nImplant chirurgical selon la revendication 1, dans le- quel l\u2019alliage de titane modifi\u00e9 est capable de sup- porter une infection tissulaire profonde \u00e0 court terme et \u00e0 long terme.\n\n55\n\n10. Implant chirurgical selon la revendication 1, compre-\n\n9\n\nEP 2 398 517 B1\n\nControl untreated titanium allo Titanium alloy with|Titanium alloy with 50Hz oxygen/100Hz oxygen PII&D treatment |PII&D treatment -- 1000W \u4e00 -40kV \u4e00 100hs 100hs \u4e00 50Hz 100Hz of] implantation \u4e00 120 120 Base pressure \u4e00 7.0x10\u00b0 Torr 7.0x10\u00b0 Torr Working pressure |-- 5x10% Torr 5x10\" Torr FIG. 1 100 1 a ie xe fot \u2014~ 80 oot \u4eba \u516d 5 ff 5 60 root = ae 8 | 5 40 \u548c 6 \\ 1 0 \u7531 \u53bf | \\ 35mm 8 20 i \u6642 1 z 7 Ng ag \u2018i. 0 | \u6709 1 0 | 50 100 150 200 250 300 1 Oxygen rich, \u2018ayer | Sputter Depth (nm) | 1 FIG. 2A\n\nControl untreated titanium allo Titanium alloy with|Titanium alloy with 50Hz oxygen/100Hz oxygen PII&D treatment |PII&D treatment -- 1000W \u4e00 -40kV \u4e00 100hs 100hs \u4e00 50Hz 100Hz of] implantation \u4e00 120 120 Base pressure \u4e00 7.0x10\u00b0 Torr 7.0x10\u00b0 Torr Working pressure |-- 5x10% Torr 5x10\" Torr\n\n10\n\nEP 2 398 517 B1\n\nAtomic Concentration (%) Atomic Concentration (%) 100 80 60 40 20 100 80 60 40 20 3 4 1 1 0 50 = * * \u7ad9 * _s \u958b -CRL------------------------- \u7ad9 -- \u2014_\u2014 a \u5716 \u4e00 / \u4e00 \u570b \u4e00 \u4e8c 7 \u4eba \u540c 1 / 100 150 \u2014m\u2014 O1s te Ti2p ee i ae | ~ 1 FIG. 2B 4 1 1 1 1 \"\u4e00 \u4e00 4 i) Lie r \u4e00 \u4e00 \u4e00 \u4e00 \u4e00 | 0 50 100 150; Oxygen rich layer 4 y9 yer _Sputter Deptt! (nm) 1 FIG. 2C 200 Oxygen rich layer Sputter Depth (nm) 1 200 3 Re RO i te wg BL, BL, eee 250 300 300\n\n11\n\nEP 2 398 517 B1\n\n12\n\nEP 2 398 517 B1\n\n160,000 140,000 120,000 100,000 80,000 60,000 Number of Adhered Bacteria 40,000 20,000 0 3 ey aba Ti alloy (control) O-PIIl 50H O-PII 100Hz FIG. 4 200um\n\n13\n\nEP 2 398 517 B1\n\n14\n\nEP 2 398 517 B1\n\nFIG. 6A FIG. 6B FIG. 6C a \u00a58 protease * \u65f6 . Cleavage linker Ant \u4e00 \u4e00 \u4e00 linker Fununu FEU moleculets) a ie [molecule(s) Antibacterial peptide Peptide \u9084 \u904e \u52a0 \u4e00 \u4e0b anoy . \u2014 Incoming S. aureus R | | icEoNECCCHoyNEUECuunr FIG, 8A CH:-CH-O CE FIG. 8B\n\n15\n\nEP 2 398 517 B1\n\nTi BNCE-C nue FIG. 8C Application of / \u6709 antibacterial layer \u2014 _ LZ FIG. 9\n\n16\n\nEP 2 398 517 B1\n\nREFERENCES CITED IN THE DESCRIPTION\n\nThis list of references cited by the applicant is for the reader\u2019s convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.\n\nNon-patent literature cited in the description\n\n\n\n\n\nR.O. DAROUICHE. Treatment of Infections Associ- ated with Surgical Implants. The New England Jour- nal of Medicine, 2004, vol. 350 (14), 1422-1429 [0002] S-H. SHIN et al. The effects of nano-silver on the proliferation and cytokine expression by peripheral blood mononuclear cells. International Immunophar- macology, 2007, vol. 7 (13), 1813-1818 [0003]\n\n\n\n\n\n\n\nB.S. ATIYEH et al. Effect of silver on burn wound infection control and healing: Review of the literature. Burns, 2007, vol. 33 (2), 139-148 [0003] S. RADIN et al. Controlled release of vancomycin from thin sol-gel films on titanium alloy fracture plate material. Biomaterials, 2007, vol. 28 (9), 1721-1729 [0004] S. RADIN et al. In vivo tissue response to resorbable silica xerogels as controlled-release materials. Bio- materials, 2005, vol. 26 (9), 1043-1052 [0004]\n\n17", "type": "Document"}}